Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As another poster pointed out its tough to take anything stated serious when eve the simplest of details are wrong. I noticed you didn't try to defend you share count comment. The current AS count is only 1,333% lower than the AS count pre split.
Emotions have no place in trading or investing. I do like the colored text in your post ??
LOL....
1. The CEO is GC not JC
2. If you truly read the filings you wouldn't claim the share structure is the same as before the RS... 150 million is slightly less than 2 million in the math classes I took.
LOL...sometimes it better to remain silent and....well I am sure you know the rest of the saying
The CEO already put the money out, it's not that hard to understand. And instead of getting money back which is owed to him, he accepted shares. Copied directly from the filing:
Shares were issued to Mr. Commissiong in lieu of repayment of certain loans made to the Company ($5k) and in lieu of interest payments made on certain senior secured non-convertible notes paid ($7k) by Mr. Commissiong on behalf of the Company.
I don't think I misunderstood. The word "we" includes the person doing the talking or typing. If not then the word "they" is typically used.
However my point stands that some are putting the cart before the horse again. The company has its own struggles then you add misinformation and you get what "we" have here.
Why would you think it would be ESS surgery news? The company hasn't even announced the results of this cGMP validation process at Lonza which must happen before any trails or surgeries can be done.
http://www.amarantus.com/news/press-releases/detail/2037/amarantus-provides-update-on-cgmp-manufacturing-validation
I hope you realize how silly that sounds. Besides here is an important note from the filing. If one is concerned about actual facts:
"Shares were issued to Mr. Commissiong in lieu of repayment of certain loans made to the Company ($5k) and in lieu of interest payments made on certain senior secured non-convertible notes paid ($7k) by Mr. Commissiong on behalf of the Company."
I caution using Twitter as a source of factual info. One glaring issue with the info you shared is that it seems to say AMBS will give away 85 million share for the new acquisition DX. This would give away majority ownership of the company, obviously not gonna happen. I could continue but need to board my flight.
Wish I knew and yes those details we all anxiously await to hear.
It's certainly not the end of the day...so not sure what you are getting at.
SAN FRANCISCO, January 15, 2016 /PRNewswire/ --
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapies in Regenerative Medicine and Orphan disease, today announced the Company will be presenting at the ICV Sonoma event. The conference is being held January 14-16, 2016 at Sonoma Golf Club in Sonoma, California. Gerald E. Commissiong, President and CEO of Amarantus, will present on Friday, January 15th, 2016 2:30pm Pacific Time.
Mr. Commissiong will discuss details regarding a pending Amarantus Diagnostics, Inc. spin-out transaction into a publicly-traded, immuno-oncology-focused diagnostics company.
Further information about ICV Sonoma can be found at: http://www.icvevents.com/event/icv-sonoma/
AMBS applied for RPDD and will likely get it along with a priority review voucher(valued at $250 million or more). That was not discussed by AMBS when SeeThruEquity did their original valuation. Might have something to do with it.
They provided a 20 plus page report, if my memory is correct, to back their valuation. You provide a couple sentences to discredit it....
Maybe you could explain further why they are so wrong. And maybe explain why ESS alone isn't worth $500 million or more. The lawsuit that kept ESS from coming to market already showed China wanted to buy ESS for more than a billion dollars.
The next two weeks will likely set the tone for AMBS for the rest of the year, IMO.
There are a couple issues with that statement:
1. I have seen the likes of Carl Icahn and Bill Ackman takes big stakes in companies and the share price continued to go down.
2. The big stake in AMBS was clearly not taken all at once but an accumulated position. Typically referred to as averaging into a position. When that happens it obviously won't cause a spike in the share price like when someone makes a huge buy.
Just keeping it real.
I have read your thoughts and opinions enough to know where you stand so please don't tell me to listen. I will manage my investment according to my own thoughts and opinions. It has served me well this far in life. I will not resort to name calling and blaming.
Exactly, perfectly stated! That is why I have been a buyer at these levels.
I do not share your view or opinion of the CEO. He will likely be seen in a different light in the near future.
My focus is on the RPDD because of the priority review voucher that could come with it.
MANF won't come into play until later in 2016 once it gets into clinical studies. Once they start to show positive data that is when the ODD's will have an affect on value, IMO.
Thanks for the kind words. I believe positive steps are being taken to shift this back onto the right track. As some have stated better financing is needed and could come as a result of current steps.
Best to you and all as we close out the year and begin new again.
No problem zynomat! I know your one of the level headed posters on this thread. I completely agree with your thoughts on the timeframe, should always be soft.
Now let's get a status update on the spin off!
Check the link I provided, it answer those type of questions.
Gerald gave a softened time frame I assume. FDA guidance says 60 days, last sentence on page 8.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf
Merry Christmas to you and all here!
That's not an attack...a yes response to those questions would be the only way he would know that. Therefore safe to say it was a silly statement.
I tend to believe anyone with a computer or who reads the paper could deduct that the NJ governor is preoccupied with other aspirations. No?
Did you miss the part where Gerald stated the spin off plan involves another DX company that is already generating revenue?
Also Amarantus cannot spin off the Dx without compensating current shareholders. Typically done by issuing dividend shares in the new company, also previously mentioned by Gerald.
LOL with only 15 million OS...ya ok
Currently it tough to say where this will go. I suspect at some point it will start to run up into JPM Conference which is the second week of January. Possibly fuel by a steady stream of news on multiple fronts. One thing is certain, GC is working his tail off to get this back in order!!
It's real easy to come on a message board and talk trash about the CEO given the rough year the company has had thus far. However he has advanced the pipeline and word is spreading. Do some DD and you will see more outlets covering Amarantus. For example the interview released today.
The DX transaction will be one of the big keys to stabilizing the pps after the conference. The other key is obtaining better financing.
Can you point me to the spot on your chart where the 31 sma or .50 has acted as "major support?" By major support I assume you mean the price has bounced from that level several times. I am not seeing it but I am not that good at technical analysis.... ; )
My charts seem to show significant support levels at .55 and .43
Very good interview, thanks for posting it! Taking note of comments made in the last minute about the DX spin off.
It's basic biotech investing 101, sorry you don't get it or choose to only spread illogical negative sediments. The more indications the higher the chance of sucess, something BP's care about.
lol, you keep believing that stuff is fluff. Should have the FDA response in next few weeks about the ODD mentioned in the PR.
Looks like you may have overlooked that .43 support zone that held. And also you show unconventional MACD numbers set up to show the cross happening. In reality the MACD did not cross bearish yet on any standard chart set-up.
The RSI(14) on the daily closed above 50 today which is generally a bullish sign.
Still not buying it....and there is plenty of reason for this to go up. It's way undervalued!
Appreciate the post Doc!! Wise words indeed, will fall on many deaf ears here.
Hey Sal - it is quite entertaining at times that's for sure. I know when I have given up on a stock I sure don't stick around. Maybe shorts are loading up with the thoughts that GC will not get the DX deal done by JPM. I would sure hate to be on the wrong side of that one.
GC stated months ago the company was focusing its resources on ESS. However he has done plenty of talking in December about the DX(LymPro and MS Precise) spin off.
He also stated in the latest interview that once the DX transactions is complete they can make big strides in a short period of time with the ALZ blood test.
Buying pressure picking up here.
I responded to your PM.
Shorts will likely cover before then.
Yes, my broker shows the same #'s.
Business is done backstage not out in the public eye. We will know soon enough if GC is bluffing or not. My bet has been placed.
To be honest I haven't really gone back to compare each filing but I do know the latest was less than the previous one.
I am merely pointing out my observations. I don't make buy recommendations, one should determine that on their own.